×
WAVE Life Sciences Net Cash Flow 2014-2025 | WVE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
WAVE Life Sciences net cash flow from 2014 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
WAVE Life Sciences Net Cash Flow 2014-2025 | WVE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
WAVE Life Sciences net cash flow from 2014 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$225.3B
Amgen (AMGN)
$164.8B
Gilead Sciences (GILD)
$144.5B
Vertex Pharmaceuticals (VRTX)
$120.6B
Bristol Myers Squibb (BMY)
$98.6B
CSL (CSLLY)
$85.4B
GSK (GSK)
$77.5B
Regeneron Pharmaceuticals (REGN)
$60.8B
Alnylam Pharmaceuticals (ALNY)
$42.9B
Argenex SE (ARGX)
$36.2B
BioNTech SE (BNTX)
$27.7B
Royalty Pharma (RPRX)
$20.6B
Insmed (INSM)
$19.7B
Biogen (BIIB)
$19.3B
Illumina (ILMN)
$17.3B
Genmab (GMAB)
$15B
Genmab (GNMSF)
$15B
Incyte (INCY)
$13.6B
Moderna (MRNA)
$13.2B
Exelixis (EXEL)
$12.4B
QIAGEN (QGEN)
$11.5B
BioMarin Pharmaceutical (BMRN)
$11.3B
Swedish Orphan Biovitrum (BIOVF)
$10.6B
Ascendis Pharma (ASND)
$10.2B
Bio-Techne Corp (TECH)
$9.2B
Exact Sciences (EXAS)
$9.1B
Verona Pharma American Depositary Share (VRNA)
$9B
Blueprint Medicines (BPMC)
$8.3B
Legend Biotech (LEGN)
$8B
Roivant Sciences (ROIV)
$7.9B